Ixoberogene soroparvovec (Ixo-vec)

About Adverum Biotechnologies

Adverum Biotechnologies is a clinical-stage biotech focused on establishing gene therapy as a transformative treatment for prevalent ocular diseases, starting with wet age-related macular degeneration (wet AMD). The company's strategy leverages a proprietary intravitreal AAV vector platform to create 'biofactories' within the eye, aiming to replace the current burdensome regimen of frequent anti-VEGF injections with a one-time, in-office therapy. Its lead candidate, Ixo-vec, is in late-stage development with the goal of providing sustained therapeutic benefit for years, potentially restoring vision and preventing blindness for millions of patients.

About Adverum Biotechnologies

Adverum Biotechnologies is a clinical-stage biotech focused on establishing gene therapy as a transformative treatment for prevalent ocular diseases, starting with wet age-related macular degeneration (wet AMD). The company's strategy leverages a proprietary intravitreal AAV vector platform to create 'biofactories' within the eye, aiming to replace the current burdensome regimen of frequent anti-VEGF injections with a one-time, in-office therapy. Its lead candidate, Ixo-vec, is in late-stage development with the goal of providing sustained therapeutic benefit for years, potentially restoring vision and preventing blindness for millions of patients.

Therapeutic Areas